Tissue | Expression Dynamics | Abbreviation |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/DPP4_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DPP4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DPP4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DPP4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00336277 | Thyroid | ATC | cell adhesion mediated by integrin | 39/6293 | 72/18723 | 2.59e-04 | 1.66e-03 | 39 |
GO:0010715 | Thyroid | ATC | regulation of extracellular matrix disassembly | 13/6293 | 17/18723 | 3.73e-04 | 2.28e-03 | 13 |
GO:00509206 | Thyroid | ATC | regulation of chemotaxis | 99/6293 | 223/18723 | 4.91e-04 | 2.86e-03 | 99 |
GO:004001316 | Thyroid | ATC | negative regulation of locomotion | 160/6293 | 391/18723 | 1.36e-03 | 7.07e-03 | 160 |
GO:003033616 | Thyroid | ATC | negative regulation of cell migration | 142/6293 | 344/18723 | 1.64e-03 | 8.22e-03 | 142 |
GO:000268818 | Thyroid | ATC | regulation of leukocyte chemotaxis | 57/6293 | 122/18723 | 1.77e-03 | 8.71e-03 | 57 |
GO:005127117 | Thyroid | ATC | negative regulation of cellular component movement | 150/6293 | 367/18723 | 1.99e-03 | 9.54e-03 | 150 |
GO:200014617 | Thyroid | ATC | negative regulation of cell motility | 147/6293 | 359/18723 | 2.01e-03 | 9.60e-03 | 147 |
GO:007169223 | Thyroid | ATC | protein localization to extracellular region | 150/6293 | 368/18723 | 2.25e-03 | 1.05e-02 | 150 |
GO:000930623 | Thyroid | ATC | protein secretion | 146/6293 | 359/18723 | 2.83e-03 | 1.29e-02 | 146 |
GO:000268519 | Thyroid | ATC | regulation of leukocyte migration | 90/6293 | 210/18723 | 3.11e-03 | 1.40e-02 | 90 |
GO:003559223 | Thyroid | ATC | establishment of protein localization to extracellular region | 146/6293 | 360/18723 | 3.20e-03 | 1.44e-02 | 146 |
GO:00336312 | Thyroid | ATC | cell-cell adhesion mediated by integrin | 11/6293 | 16/18723 | 4.33e-03 | 1.80e-02 | 11 |
GO:005070815 | Thyroid | ATC | regulation of protein secretion | 109/6293 | 268/18723 | 8.87e-03 | 3.36e-02 | 109 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DPP4 | SNV | Missense_Mutation | novel | c.1444N>A | p.Leu482Ile | p.L482I | P27487 | protein_coding | deleterious(0.05) | benign(0.258) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DPP4 | SNV | Missense_Mutation | rs755540270 | c.1051N>G | p.Thr351Ala | p.T351A | P27487 | protein_coding | deleterious(0.02) | benign(0.112) | TCGA-AR-A2LK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | PD |
DPP4 | SNV | Missense_Mutation | | c.1394N>T | p.Ala465Val | p.A465V | P27487 | protein_coding | deleterious(0.01) | possibly_damaging(0.675) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
DPP4 | SNV | Missense_Mutation | | c.2222N>A | p.Gly741Glu | p.G741E | P27487 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-B6-A0X1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
DPP4 | SNV | Missense_Mutation | | c.779N>C | p.Gly260Ala | p.G260A | P27487 | protein_coding | deleterious(0.01) | probably_damaging(0.928) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
DPP4 | SNV | Missense_Mutation | novel | c.1493N>T | p.Ser498Leu | p.S498L | P27487 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
DPP4 | SNV | Missense_Mutation | rs752793888 | c.1067N>A | p.Arg356Lys | p.R356K | P27487 | protein_coding | tolerated(0.52) | benign(0.084) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DPP4 | SNV | Missense_Mutation | | c.67N>A | p.Val23Met | p.V23M | P27487 | protein_coding | tolerated(0.16) | probably_damaging(0.988) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DPP4 | deletion | Frame_Shift_Del | rs779957190 | c.135_138delAACT | p.Thr46IlefsTer3 | p.T46Ifs*3 | P27487 | protein_coding | | | TCGA-A2-A3XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamyicin | CR |
DPP4 | SNV | Missense_Mutation | | c.2072N>C | p.Arg691Thr | p.R691T | P27487 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2105762 | OMARIGLIPTIN | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | VILDAGLIPTIN | VILDAGLIPTIN | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Beta-phe compound 2 | | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Imidazo cyclohexylamine derivative 3 | | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Peptide analog 47 | | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | ENALAPRIL | ENALAPRIL | 16678199 |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Dutogliptin | DUTOGLIPTIN | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3833357 | BEGELOMAB | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | 363894186 | TALABOSTAT | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | PMID25482888-Compound-52 | | |